Concert Successfully Completes Phase 2 Trial Evaluating of CTP-543

September 3rd, 2019

Concert Pharmaceuticals has successfully completed its dose-ranging Phase 2 trial with CTP-543. Subject to FDA feedback, we anticipate these trial results will support advancing into our Phase 3 program in 2020.

“We are extremely grateful to the patients who are participating in our clinical trials to support our mission to develop a new treatment for alopecia areata,” said James V. Cassella, Ph.D., Chief Development Officer of Concert Pharmaceuticals.

We reported results today and expect to present the full Phase 2 results at a future medical conference.

CTP-543, an oral selective inhibitor of Janus kinases JAK1 and JAK2, is in clinical development for the treatment of moderate-to-severe alopecia areata. CTP-543 is an investigational drug and has not been approved by the FDA or any regulatory authority for any use.

 

Back to Top